Pfizer's next-generation ALK/ROS1 inhibitor, lorlatinib, granted breakthrough therapy designation from FDA for alk-positive metastatic non-small cell lung cancer

28th April 2017 Uncategorised 0

Pfizer

More: Pfizer's next-generation ALK/ROS1 inhibitor, lorlatinib, granted breakthrough therapy designation from FDA for alk-positive metastatic non-small cell lung cancer
Source: MDlinx